Global Picato Gel (Ingenol Mebutate) Market Size, Share, and COVID-19 Impact Analysis, By Product Type (0.015% and 0.05%), By Indications (Skin Cancer, Actinic Keratosis, and Others), By Distribution Channel (Online Pharmacies, Hospitals, Dermatology Clinics, and Others), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2023 - 2033

Global Picato Gel (Ingenol Mebutate) Market Insights Forecasts to 2033

• The Global Picato Gel (Ingenol Mebutate) Market Size Was Estimated at USD 506.23 Million in 2023
• The Market Size is Expected to Grow at a CAGR of around 8.28% from 2023 to 2033
• The Worldwide Picato Gel (Ingenol Mebutate) Market Size is Expected to reach USD 1121.07 Million By 2033
• Asia Pacific is Predicted to Grow at the fastest CAGR throughout the projection period

The Global Picato Gel (Ingenol Mebutate) Market Size is Predicted to Exceed USD 1121.07 Million By 2033, Growing at a CAGR of 8.28% from 2023 to 2033.

Market Overview

The picato gel (ingenol mebutate) market comprises the development, formulation, and commercialization of the picato gel containing ingenol mebutate as an active pharmaceutical ingredient used for the treatment of actinic keratosis topically. Ingenol mebutate is obtained from the Euphoria peplus, is a traditional medicine used in the management of skin conditions like warts and cancer. Ingenol mebutate is a well-tolerated treatment for actinic keratosis, with good patient adherence due to its short treatment period. Available in two strengths for different sites, it is a clear, colorless gel base. Picato® gel, 0.015% and 0.05%, contains 150 and 500 mcg of ingenol mebutate, respectively, in each gram of gel, consisting of isopropyl alcohol, hydroxyethyl cellulose, citric acid, monohydrate, sodium citrate, benzyl alcohol, and purified water. It is for external use only.

Several pharmaceutical companies are analyzing the prevalence rate of actinic keratosis, which drives the market growth. For instance, actinic keratosis (AK) is a common dermatological condition with an estimated prevalence of 13.3% in the European population. The incidence has increased due to an aging population and changes in people's behaviours, leading to increased exposure to UV radiation. Almirall has released new data revealing that over one-third of people with AK don't know the cause of the condition. A survey showed that 57.80% of the population has never had their skin checked by a professional. AK Global Day was created in 2022 to raise awareness of AK, and Almirall's campaign, "Stay Vigilant," aims to raise awareness about the relationship between the disease and prolonged exposure to sunlight. 85% of those surveyed were unaware of AK.

Report Coverage

This research report categorizes the global picato gel (ingenol mebutate) market based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. The report analyzes the key growth drivers, opportunities, and challenges influencing the global picato gel (ingenol mebutate) market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyzes their core competencies in each sub-segment of the global picato gel (ingenol mebutate) market.

Driving Factors:

Increasing prevalence of actinic keratosis (AK):

Actinic keratosis (AK) is a chronic skin disease caused by prolonged exposure to UV radiation and other risk factors like immunosuppression. It has a global prevalence rate of 14%, indicating a significant global disease burden. AKs are precancerous epidermal lesions that develop in sensitive, frequently sun-exposed skin, causing multiple, red, scaly patches. The main risk factor for AK development is cumulative UV radiation exposure throughout one's lifetime, with age, sex, and skin phototype being independent factors. AKs are more frequently located on the head and upper extremities, where sun exposure is greatest. Hence, growing cases of actinic keratosis among the worldwide population drive the market growth.

Growing preference for the topical treatments:

Topical treatments are increasingly preferred by patients and healthcare providers due to their convenience, ease of use, and lower risk of systemic side effects. These treatments are applied directly to the affected area, targeting specific lesions or affected areas and minimizing systemic side effects. Patients often prefer these treatments over surgical or procedural options as they avoid the risks and recovery time associated with surgical procedures. Picato Gel, which targets specific lesions of AK, aligns with this trend, making it a favorable choice for both patients and dermatologists. Therefore, the rising demand for the topical treatment for the management of actinic keratosis leads to the expansion of the market.

Restraining Factors

Picato gel, a treatment for actinic keratosis, faces regulatory scrutiny due to safety and efficacy concerns. Side effects and other alternative treatments may deter patients and healthcare providers. The high price may also pose a barrier, particularly in regions with limited healthcare coverage, resulting in the suppression of market growth.

Market Segmentation

The global picato gel (ingenol mebutate) market share is classified into product type, indications, and distribution channel.

• The 0.015% segment accounted for the largest share in 2023 and is anticipated to grow at a significant CAGR throughout the forecast period.

Based on the product type, the global picato gel (ingenol mebutate) market is categorized into 0.015% and 0.05%. Among these, the 0.015% segment accounted for the largest share in 2023 and is anticipated to grow at a significant CAGR throughout the forecast period. The segment's growth is attributed to the targeted treatment, increasing the proportion of the geriatric population, increasing prevalence of the actinic keratosis, minimal systemic absorption, and enhanced patient compliance.

• The actinic keratosis segment accounted for the largest market share in 2023 and is expected to grow at a significant CAGR throughout the projected timeframe.

Based on the indications, the global picato gel (ingenol mebutate) market is categorized into skin cancer, actinic keratosis, and others. Among these, the actinic keratosis segment accounted for the largest market share in 2023 and is expected to grow at a significant CAGR throughout the projected timeframe. The segment's growth is attributed to the increasing prevalence of actinic keratosis, prolonged exposure of an individual to UV radiation, genetic predisposition, and low immunity individuals are more susceptible to actinic keratosis.

• The hospitals segment held the largest share in 2023 and is predicted to grow at a significant CAGR throughout the projected timeframe.

Based on the distribution channel, the global picato gel (ingenol mebutate) market is categorized as online pharmacies, hospitals, dermatology clinics, and others. Among these, the hospitals segment held the largest share in 2023 and is predicted to grow at a significant CAGR throughout the projected timeframe. The segmental expansion is owing to the increasing in-patient and outpatient services, availability of the dermatologist, increasing admission of the geriatric population, collaboration of the private and government hospitals, and provisions of the healthcare policies.

Regional Segment Analysis of the Global Picato Gel (Ingenol Mebutate) Market

• North America (U.S., Canada, Mexico) 
• Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
• Asia-Pacific (China, Japan, India, Rest of APAC)
• South America (Brazil and the Rest of South America) 
• The Middle East and Africa (UAE, South Africa, Rest of MEA)

North America is anticipated to hold the largest share of the global picato gel (ingenol mebutate) market over the predicted timeframe.

North America is anticipated to hold the largest share of the global picato gel (ingenol mebutate) market over the predicted timeframe. This is due to the prevalence of skin disorders and established healthcare infrastructure, particularly in the United States, where actinic keratosis and skin cancer are prevalent. The region's strong focus on research and pharmaceutical companies supports market growth. Canada and Mexico also show steady growth due to rising healthcare infrastructure and increased awareness of skin disorders.

Asia Pacific is anticipated to grow at the fastest CAGR throughout the projected timeframe. The Asia Pacific market for skincare products is expanding due to rising disposable incomes, improved healthcare infrastructure, and increased skin health awareness. Countries like China and India are emerging as significant markets due to their large populations and growing middle-class segments. Government initiatives to improve healthcare access and spending further support market growth. The rising prevalence of actinic keratosis and the awareness of early skin cancer prevention are driving demand. Innovations in topical formulations and improved healthcare infrastructure are enhancing the appeal of products like picato gel.

Competitive Analysis:

The report offers an appropriate analysis of the key organizations/companies involved within the global picato gel (ingenol mebutate) market, along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Sun Pharmaceutical Industries Ltd.
• Sanofi S.A.
• GlaxoSmithKline plc
• Novartis AG
• AbbVie Inc.
• Valeant Pharmaceuticals International, Inc.
• Roche Holdings AG
• Allergan plc
• Leo Pharma
• Teva Pharmaceutical Industries Ltd.
• Galderma S.A.
• AstraZeneca plc
• Pfizer Inc.
• Bayer AG
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs) 

Market Segment

This study forecasts revenue at global, regional, and country levels from 2023 to 2033. Spherical Insights has segmented the global picato gel (ingenol mebutate) market based on the below-mentioned segments:

Global Picato Gel (Ingenol Mebutate) Market, By Product Type

• 0.015%
• 0.05%

Global Picato Gel (Ingenol Mebutate) Market, By Indications

• Skin Cancer
• Actinic Keratosis
• Others

Global Picato Gel (Ingenol Mebutate) Market, By Distribution Channel

• Online Pharmacies
• Hospitals
• Dermatology Clinics
• Others

Global Picato Gel (Ingenol Mebutate) Market, By Region

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa